Biosilicate® Ototoxicity and Vestibulotoxicity evaluation in guinea-pigs

Abstracts

As alterações, destruições e interrupções da arquitetura da cadeia ossicular da orelha média podem ser causadas por infecções, trauma, tumores, alterações congênitas ou cirurgias prévias. Entretanto os processos inflamatórios e infecciosos, focais ou generalizados que acometem a orelha média são os mais prevalentes, gerando uma enorme demanda de ossiculoplastias. O Biosilicato® é um novo material que pode ser usado em orelhas médias com o objetivo de reconstruir a cadeia ossicular. Constitui-se de uma vitrocerâmica bioativa do tipo A, ou seja, que se liga a tecido ósseo ou a tecido mole em algumas horas, devido à formação de hidroxicarbonatoapatita em sua superfície de contato quando em contato com fluidos corpóreos. OBJETIVO: O objetivo deste trabalho é avaliar a ototoxicidade e vestibulotoxicidade do Biosilicato em cobaias, para posterior utilização em humanos. MATERIAL E MÉTODO: Trata-se de um estudo clínico e experimental, onde foram realizadas emissões otoacústicas antes e após a colocação de Biosilicato na orelha média de cobaias e realizada microscopia eletrônica de varredura da cóclea, sáculo, utrículo e máculas dos canais semicirculares após 30 e 90 dias para avaliar a oto e vestibulotoxicidade. RESULTADOS: Não houve sinais de oto ou vestibulotoxicidade em nenhum dos grupos relacionados ao Biosilicato. CONCLUSÃO: O Biosilicato é um material seguro para ser usado em ossiculoplastias.

orelha média; prótese ossicular; toxicidade

ORIGINAL ARTICLE

Biosilicate® Ototoxicity and Vestibulotoxicity evaluation in guinea-pigs

Eduardo Tanaka Massuda^I; Lucas Lisboa Maldonado^II; Jessé Teixeira de Lima Júnior^III; Oscar Peitl^IV; Miguel Ângelo Hyppolito^V; José Antonio Apparecido de Oliveira^VI

^IPhD, Assistant Professor - Department of Ophthalmology, ENT and Head and Neck Surgery of the Ribeirão Preto Medical School - University of São Paulo (USP)

^IIENT Resident Physician - - Department of Ophthalmology, ENT and Head and Neck Surgery of the Ribeirão Preto Medical School - University of São Paulo (USP)

^IIIENT Resident Physician - - Department of Ophthalmology, ENT and Head and Neck Surgery of the Ribeirão Preto Medical School - University of São Paulo (USP)

^IVPhD, Professor of Materials Engineering - Federal University of São Carlos

^VPhD, Assistant Professor - Department of Ophthalmology, ENT and Head and Neck Surgery of the Ribeirão Preto Medical School - University of São Paulo (USP)

^VIFull Professor - Department of Ophthalmology, ENT and Head and Neck Surgery of the Ribeirão Preto Medical School - University of São Paulo (USP)

SUMMARY

Changes, destructions and interruptions in middle ear ossicular chain architecture may be caused by infection, trauma, tumors, congenital alterations or prior surgeries. Nonetheless, infectious and inflammatory processes, focal or generalized which affect the middle ear are the most prevalent, causing a great demand for ossiculoplasty. Biosilicato® is a new material which can be used in the middle ear with the goal of reconstructing the ossicular chain. It is a bioactive type A vitroceramic, in other words, it binds to bone or soft tissue in a matter of a few hours, thanks to the formation of hydroxy-carbonateapatatie in its contact surface when in contact with body fluids.

AIMS: The goal of the present paper is to assess biosilicate ototoxicity and vestibular toxicity in experimental animals, for later use in humans.

MATERIALS AND METHODS: This a clinical and experimental study in which otoacoustic emissions were performed before and after the placement of Biosilicate in the middle ear of experimental animals and a scanning electron microscopy was carried out in the cochlea, saccule, utriculus and macula of the semicircular canals after 30 and 90 days to assess oto and vestibular toxicity.

RESULTS: There were no signs of oto or vestibular toxicity in any of the groups associated with biosilicate.

CONCLUSION: Biosilicate is a safe material to be used in ossiculoplasties

Keywords: middle ear, ossicular prosthesis, toxicity.

INTRODUCTION

Changes, destructions and interruptions in the middle ear ossicular chain in humans may be of infectious origin, trauma, tumor, congenital or due to prior surgery. Nonetheless, infectious inflammatory processes¹, focal or generalized which affect the middle ear are the most prevalent. This disease is defined as otitis media.

Otitis media affects 2% of the population, and 8% of school age children. It affects millions of persons every year, generating huge financial costs².

Thus, if we analyze only the number of chronic otitis media and its many variations: cholesteatoma, cholesterol granuloma, adhesive otitis, granulomatous otitis, the percentage of people who may require surgical intervention to correct ossicles defects is enormous. Surgeries for the reconstruction of the ossicular chain are called ossiculoplasties. The first reconstructions were made by Wullstein in 1956³.

Different materials are used in ossiculoplasties, all with good results⁴, which according to their own nature and origin are called autografts, homografts and synthetic prosthesis⁵.

The autografts⁶ are the remains of the ossicles, cranial cortical bones⁷ and cartilage of the patient⁸.

The homologous grafts are ossicles obtained from banks of organ donation; however, they are no longer used because of AIDS.

Synthetic materials are the ones most used. Among them we have titanium prosthesis^9-11, ceramic^12,13, hydroxiapatite^14,15, plastipore¹⁶, and bone cement¹⁷.

Biosilicate® is a new material which can be used in middle ears with the goal of reconstructing the ossicular chain. It is type A bioactive vitroceramic, it binds to the bone tissue or soft tissue in a few hours, because hydroxyapatite forms on its contact surface when in contact with body fluids¹⁸.

The goal of the present study was to assess biosilicate ototoxicity and vestibulotoxicity in laboratory animals, for later use in humans.

MATERIALS AND METHODS

According to approval by the Ethics Committee under protocol # 046/2005, we used 15 albino male lab animals weighing between 400g to 600g, with Preyer's reflex present and Distortion Product Otoacoustic Emissions (ILO 92 CAE System otodynamics LTD equipment) present in both sides. These otoemissions were measured in the pre and postoperative (before the animals were slaughtered) without sedation, and then the animals were broken down into 3 groups of 5 animals in each.

These animals were anesthetized with intraperitoneal pentobarbital 40mg/kg and injected with penicillin; immediately after we injected the retroauricular region with 2% xylocaine associated to adrenalin 1:200.000 bilaterally. A 1cm retroauricular incision was made all the way to the bulla, causing bilateral exposure; a bone window was open under microscopic view (DF Vasconcellos Microscope) to access the middle ear.

In groups 1 and 2 we used powder Biosilicate® (Fig. 1), closing the bulla with bone cement in a total of 10 lab animals. In Group 3 (control) the bulla was opened and closed immediately after opening with dental cement.

In Group 1, the animals were slaughtered 30 days later and in Group 2 and 3 they were slaughtered 90 days after the surgical procedure. Their cochleas, saccule, utricle and vestibular ampullae were removed for scanning electron microscopy (SEM).

The animals were slaughtered in a scheduled fashion under anesthesia by ether, and they were later beheaded in order to remove the cochlea from their bullas.

With microscopic dissection the cochleas were soaked in a fixation solution of 3% Glutaraldehyde at 4º Celsius and kept in solution for 24 hours for fixation purposes. The steps that followed were carried out at the Electron Microscopy Lab of the Molecular and Cellular Biology and Pathogenic Bioagents Department.

The 3% glutaraldehyde solution in 0.1M, pH = 7.4 phosphate buffer was injected in the cochleas through the round window for 4 hours at 4º Celsius, flushed three times for 5 minutes with the same buffer solution, afterwards they were fixed with 1% osmium tetroxide for 2 hours at 4º Celsius and were submitted to dehydration at room temperature and in an increasing battery of ethanol (50%, 70%, 90% and 95% - once, for 10 minutes in each concentration) and absolute ethanol three times for 15 minutes. After dehydration, it was dried by the CO₂ critical point method, when the water was taken off the material. After being fixed in a proper specimen holder, the material was coated with gold vapors in a vacuum chamber and examined under SEM (Jeol JSM 5200 microscope).

After photographed, the results obtained from the SEM were analyzed through cochleograms. We counted the number of outer hair cells on the cochlear basal turn in a certain photographic fields and we counted 10 cells, present or absent.

The saccular and utricle maculae, as well as the ampullae of the semi-circular canals were prepared the same way as the cochlea and assembled on a separate specimen holder. We established that the damage to the vestibular neuroepithelium would be based on the disappearance or rarefaction of the stereocilia bundles of the vestibular hair cells assessed by SEM.

RESULTS

All the 5 lab animals (10 ears) which were slaughtered within 30 days presented inner and external hair cells preserved without any sign of ototoxicity (Fig. 2) when assessed by SEM. We carried out the Fisher's exact test (p<0.05 significance level) with a p=1 result, indicating no ototoxicity in the otosilicate group, statistically significant.

The laboratory animals which were slaughtered within 90 days had otosilicate in Group 2, and only bulla cover in Group 3 (5 animals in each group), making up a total of 20 ears, did not show signs of ototoxicity (Fig. 3). Through the Fisher's exact test, p=1, there was no ototoxicity in groups 2 and 3, with statistical significance.

We did not observe signs of vestibulotoxicity in the animals tested within 30 and 90 days of exposure to otosilicate (p>0.05). (Figs. 4 and 5)

DISCUSSION

Different animal models were tested in order to assess the ototoxicity of biocompatible materials for use as prosthesis in the middle ear such as rats¹⁹, mice²⁰, guinea pigs²¹, rabbits1, cats²². Zikk et al.²¹ utilized ceravital grains, not observing hearing loss measured by the brainstem evoked auditory potential in 100% of the animals.

The otosilicate (biosilicate®) proved not ototoxic or vestibulotoxic for the guinea pigs tested, there was no destruction of inner or outer hair cells within 30 and 90 days of exposure, proving to be a material of good tolerability and compatibility as already shown in other studies¹⁸. In the study by Moura (2007) they also observed the formation of hydroxycarbonate apatite on the otosilicate surface after 24 hours, in cell culture liquid, showing its high bioactivity (class A). With this accelerated in vitro osteogenesis, there is a lower likelihood of extrusion of such material in the postoperative of ossiculoplasties.

Thus, by approval from the ethics committee of experimentation in humans, we started to use this material as middle ear prosthesis in humans, partial prosthesis - when we have the stapes or total prosthesis when we place the prosthesis directly on the stapes footplate. We started the surgical procedures in humans, expecting to be successful on the first results obtained; however, because of the reduced number of cases and the restricted follow up time, this study must be expanded.

CONCLUSION

Otosilicate (biosilicate®) did not present ototoxicity or vestibulotoxicity for the lab animals studied, proving to be a safe and promising material to be used as a prosthesis for ossicular reconstruction in humans.

Paper submitted to the BJORL-SGP (Publishing Management System - Brazilian Journal of Otorhinolaryngology) on July 14, 2008; and accepted on October 20, 2008. cod. 5939

• 1. Reck R. Bioactive glass-ceramics in ear surgery: animal studies and clinical results. Laryngoscope. 1984; 94(2 Pt 2 Suppl 33):1-54.
• 2. Caldas N, Caldas Neto SS. Reconstrução ossicular do ouvido médio - custos versus resultados. Rev Bras Otorrinolaringol. 1989;55(3):127-32.
• 3. Wullstein H. The restoration of the function of the middle ear, in chronic otitis media. Ann Otol Rhinol Laryngol. 1956;65(4):1021-41.
• 4. Neto S C, Ganança F F, Caldas N. Reconstrução ossicular em timpanosclerose. Rev Bras Otorrinolaringol. 1991;57(3):128-34.
• 5. Arnaldo Linden A, Costa S S, Smith M M. Timpanoplastia: Evolução nas técnicas de reconstrução de cadeia ossicular. Rev Bras Otorrinolaringol. 2000;66(2):136-42.
• 6. Desaulty A, Shahsavari S, Pasquesoone X. Ossicular reconstruction with autograft in type III. Rev Laryngol Otol Rhinol. (Bord) 2005;126(1):19-23.
• 7. Romanet P, Duvillard C, Delouane M. Mastoid cortical bone grafts in ossiculoplasty. Ann Otolaryngol Chir Cervicofac. 2000;117(2):105-9.
• 8. Neumann A, Schultz-Coulon HJ, Jahnke K. Type III tympanoplasty applying the palisade cartilage technique: a study of 61 cases. Otol Neurotol. 2003;24(1):33-7.
• 9. Stupp CH, Stupp HF, Grun D. Replacement of ear ossicles with titanium prostheses. Laryngorhinootologie. 1996;75(6):335-7.
• 10. Nguyen DQ, Lavieille JP, Schmerber S. Failure rate and revision surgery in ossiculoplasty with Kurz titanium prosthesis. Rev Laryngol Otol Rhinol. (Bord) 2004;125(3):157-62.
• 11. Ho SY, Battista RA, Wiet RJ. Early results with titanium ossicular implants. Otol Neurotol. 2003;24(2):149-52.
• 12. Reck R, Helms J. The bioactive glass ceramic Ceravital in ear surgery. Five years experience. Am J Otol. 1985;6(3):280-3
• 13. Niparko JK, Kemink JL, Graham MD, Kartush JM. Bioactive glass ceramic in ossicular reconstruction: a preliminary report. Laryngoscope. 1988;98(8 Pt 1): 822-5.
• 14. Folia M, Abedipour D, Naiman N, Truy E. Revision ossiculoplasty: anatomical and functional results. Rev Laryngol Otol Rhinol. (Bord) 2006;127(3):121-5.
• 15. Truy E, Naiman AN, Pavillon C, Abedipour D, Lina-Granade G, Rabilloud M. Hydroxyapatite versus titanium ossiculoplasty. Otol Neurotol. 2007;28(4):492-8.
• 16. Shea JJ, Emmett JR. Biocompatible ossicular implants. Arch Otolaryngol. 1978;104(4):191-6.
• 17. Hoffmann KK, Kuhn JJ, Strasnick B. Bone cements as adjuvant techniques for ossicular chain reconstruction. Otol Neurotol. 2003;24(1):24-8.
• 18. Moura J, Teixeira LN, Ravagnani C, Peitl O, Zanotto ED, Beloti MM, et al. In vitro osteogenesis on a highly bioactive glass-ceramic (Biosilicate). J Biomed Mater Res. A2007;82(3):545-57.
• 19. Pinilla M, Ramirez-Camacho R, Jorge E, Trinidad A, Vergara J. Ventral approach to the rat middle ear for otology research. Otolaryngol Head Neck Surg. 2001;124(5):515-7.
• 20. Kawanabe K, Yamamuro T, Nakamura T, Kotani S. Effects of injecting massive amounts of bioactive ceramics in mice. J Biomed Mater Res. 1991;25(1):117-28.
• 21. Zikk D, Rapoport Y, Bloom J, Himelfarb MZ. Auditory brain-stem responses in guinea pigs following middle ear implantation of Ceravital. Eur Arch Otorhinolaryngol. 1990;248(2):102-4.
• 22. Mischke RE, Hyams V, Shea JJ, Gross CW. Proplast in the middle ear and oval window of cats. Arch Otolaryngol. 1977;103(8):489-92.

Publication Dates

• Publication in this collection
  03 Nov 2009
• Date of issue
  Oct 2009

History

• Accepted
  20 Oct 2008
• Received
  14 July 2008